Exclusive distribution agreement for rare disease therapy strengthens the specialty pharmacy’s footprint beyond oncology

CARY, N.C. (March 21, 2019) Biologics by McKesson continues to expand its capabilities as a specialty pharmacy expert in oncology and complex conditions through a new exclusive distribution agreement. After making recent investments to leverage more than 25 years of oncology experience into other complex conditions, Biologics has been selected by Sanofi Genzyme as the exclusive specialty pharmacy provider for CABLIVITM (caplacizumab). In addition to CABLIVI, Biologics is included in distribution agreements for six other therapies for complex conditions.

CABLIVI was approved by the FDA on Feb. 6 for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare, life threatening blood-clotting disorder. CABLIVI is the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with aTTP.

Given the acute nature of the condition, patients need rapid and seamless access to treatment. To support this and the launch of CABLIVI and other complex therapies, Biologics designed a specialty pharmacy program that pairs its industry-leading, high-touch pharmacy solutions with enhanced patient access services that ensure patients receive affordable therapy quickly. This enhanced program incorporates Biologics’ innovative PharmacyEliteTM solution and allows the company to extend its offering for both patients and biopharmaceutical customers beyond traditional pharmacy support. Through PharmacyElite, Biologics offers enhanced patient access services that help eligible patients being treated with CABLIVI enroll in copay assistance and patient assistance programs (PAPs).

“For more than 25 years, Biologics has helped cancer patients navigate the complex healthcare landscape to gain access to therapies and deliver personalized support designed to improve patient outcomes,” said Brandon Tom, vice president, commercial services, Biologics by McKesson. “We are proud to continue to expand our offering to the same high-touch specialty pharmacy solutions for patients with complex conditions beyond oncology and look forward to helping these patients get the specialty medication, access and support they need.”

Biologics’ specialty pharmacy is committed to and recognized for its exceptional level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes a pharmacist with in-depth knowledge of therapies, an experienced nurse and a financial counselor familiar with various financial assistance programs and organizations that help patients. This greatly-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians can submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians can search for Biologics within their EMR system.


About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

Claire Crye, Public Relations
t 281.825.9927 claire.crye@mckesson.com